EPZ020411
CAS No. : 1700663-41-7
| Size | Price | Stock |
|---|---|---|
| 5mg | $165 | In-stock |
| 10mg | $275 | In-stock |
| 50mg | $715 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-12970 |
| M.Wt: | 442.59 |
| Formula: | C25H38N4O3 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
EPZ020411 is a selective inhibitor of PRMT6 with an IC50 of 10 nM, has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 can be used for the research of cancer[1][2]. IC50 & Target: IC50: 0.01 μM (PRMT6), 0.119 μM (PRMT1), 0.223 μM (PRMT8)[1] In Vitro: EPZ020411 (0-20 μM; 24 h) decreases H3R2 methylation in A375 cells[1]. EPZ020411 (20-40 μM; 6 h) reduces neomycin- and cisplatin-induced cell apoptosis and increases hair cell survival[2]. In Vivo: EPZ020411 (10 mg/kg; i.p. once) reduces neomycin- and cisplatin-induced hearing loss in C57BL/6J wild-type mice with acute ototoxicity model[2].
| Rats IV 1 mg/kg |
Rats SC 5 mg/kg |
|
| CL (mL/min/kg) | 19.7±1.0 | |
| Vss (L/kg) | 11.1±1.6 | |
| t1/2 (h) | 8.54±1.43 | 9.19±1.60 |
| tmax (h) | 0.444 | |
| Cmax (ng/mL) | 844±306 | |
| AUC0-τ (h·ng/mL) | 745±34 | 2456±135 |
| AUC0-inf (h·ng/mL) | 846±45 | 2775±181 |
| F (%) | 65.6±4.3 |
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- EPZ020411
- Cat. No.:
- HY-12970
- Quantity:
Your information is safe with us.